Merck Announces FDA Approval of Ebola Zaire Vaccine Ervebo
Treatment indicated for patients aged 12 months and older.
Merck has revealed the FDA approval of an expanded indication for Ervebo, for the prevention of disease caused by Zaire ebolavirus for individuals aged one year and older. Initially, the vaccine had been approved for patients aged 18 and older. The treatment does not support other ebolavirus variants and the current duration of protection is unknown.
“Ebola virus disease is contagious and potentially deadly in both children and adults. We’re proud of the approval of ERVEBO for the prevention of disease caused by Zaire ebolavirus in children as young as 12 months old, which is another milestone in our continued commitment to help address the global health threat caused by Zaire ebolavirus,” said Eliav Barr, SVP, head of global clinical development and chief medical officer, Merck Research Laboratories, in a company press release.
Reference: U.S. FDA Approves Merck’s ERVEBO® (Ebola Zaire Vaccine, Live) for Use in Children 12 Months of Age and Older. Merck. August 3, 2023. Accessed August 8, 2023. https://www.merck.com/news/u-s-fda-approves-mercks-ervebo-ebola-zaire-vaccine-live-for-use-in-children-12-months-of-age-and-older/
The Misinformation Maze: Navigating Public Health in the Digital Age
March 11th 2025Jennifer Butler, chief commercial officer of Pleio, discusses misinformation's threat to public health, where patients are turning for trustworthy health information, the industry's pivot to peer-to-patient strategies to educate patients, and more.
Navigating Distrust: Pharma in the Age of Social Media
February 18th 2025Ian Baer, Founder and CEO of Sooth, discusses how the growing distrust in social media will impact industry marketing strategies and the relationships between pharmaceutical companies and the patients they aim to serve. He also explains dark social, how to combat misinformation, closing the trust gap, and more.
